Gilead Sciences Inc. closed 10.06% short of its 52-week high of $119.96, which the company achieved on March 10th.

RBC Capital analyst Brian Abrahams maintained a Hold rating on Gilead Sciences (GILD – Research Report) today and set a price target of $90.00.

Grand Rapids applied for — and was denied — an exemption for its 'Thunderhawks' mascot, and has pushed back against what it ...

Oppenheimer notes that Gilead (GILD) shares are weak today following reports from multiple media outlets that the Health and Human Services ...